Pneumatosis intestinalis and imatinib mesylate

Ann Hematol. 2014 Oct;93(10):1783-4. doi: 10.1007/s00277-014-2051-y. Epub 2014 Mar 20.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Asparaginase / administration & dosage
  • Benzamides / administration & dosage
  • Benzamides / adverse effects*
  • Child, Preschool
  • Dasatinib
  • Daunorubicin / administration & dosage
  • Dexamethasone / administration & dosage
  • Drug Substitution
  • Female
  • Humans
  • Imatinib Mesylate
  • Parenteral Nutrition, Total
  • Piperazines / administration & dosage
  • Piperazines / adverse effects*
  • Pneumatosis Cystoides Intestinalis / chemically induced*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects*
  • Pyrimidines / administration & dosage
  • Pyrimidines / adverse effects*
  • Recurrence
  • Thiazoles / administration & dosage
  • Vincristine / administration & dosage

Substances

  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Vincristine
  • Dexamethasone
  • Imatinib Mesylate
  • Asparaginase
  • Dasatinib
  • Daunorubicin